Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04243382
Other study ID # SHEBA-18-5105-OBY-CTIL
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 27, 2020
Est. completion date December 2024

Study information

Verified date January 2021
Source Sheba Medical Center
Contact Omer Bar-Yosef, MD.PHD
Phone 972-35302895
Email Omer.BarYosef@sheba.health.gov.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a phase II, prospective, double blind, placebo-controlled study of the efficacy of autologous umbilical cord blood infusion. The study population will consist of 60 children ages 18 months to 12 years with ASD. The population will be randomly assigned to 2 groups, the study group be treated by cord blood in the beginning of the study and the control group by placebo product. The study will consist of 4 stages Stage 1: initial assessment by physiotherapist and occupational therapist / treatment by cord blood or placebo / blood work before and after treatment Stage 2: at stage 1 + 6 months assessment by physiotherapist and occupational therapist / cross-over treatment by cord blood or placebo / blood work before and after treatment Stage 4: at stage 1 + 12 months assessment by physiotherapist and occupational therapist The primary outcome is improvement of social communication skills six months after treatment at stage 1


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Months to 12 Years
Eligibility Inclusion Criteria: - Age = 1.5 years to = 12 years (11 years, 364 days) at the time of visit 1 - Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using the DSM-5 criteria - Fragile X testing performed and negative - Available and qualified umbilical cord blood unit with a minimum banked total nucleated cell dose of = 2 x 10e7 cells/kg - Stable on current psychiatric medication regimen (dose and dosing schedule) for at least 2 months prior to infusion of study product - Normal absolute lymphocyte count (=1500/uL) - Able to travel to Sheba Medical Center University three times (baseline, 6 and 12 months post-baseline), and parent/guardian is able to participate in interim surveys and interviews monthly - Parental consent Exclusion Criteria - General: - Review of medical records indicates ASD diagnosis not likely - Known diagnosis of any of the following coexisting psychiatric conditions: depression, bipolar disorder, schizophrenia, obsessive compulsive disorder - Screening data suggests that participant would not be able to comply with the requirements of the study procedures, including study outcome measures, as assessed by the study team - Family is unwilling or unable to commit to participation in all study-related assessments, including follow up for approximately 12 months - Genetic: - Records indicate that child has a known genetic syndrome such as (but not limited to) Fragile X syndrome, neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cystic fibrosis, muscular dystrophy - Known pathogenic copy number variation (CNV) associated with ASD (e.g., 16p11.2, 15q13.2, 2q13.3) - Infectious: - Known active CNS infection - Evidence of uncontrolled infection based on records or clinical assessment - HIV positivity - 4 Medical: - Known metabolic disorder - Known mitochondrial dysfunction - History of unstable epilepsy or uncontrolled seizure disorder, Lennox Gastaut syndrome, Dravet syndrome, or other similar epileptic encephalopathy - Concurrent genetic or acquired disease or comorbidity(ies) that could require a future stem cell transplant - Significant sensory (e.g., blindness, deafness, uncorrected hearing impairment) or motor (e.g., cerebral palsy) impairment - Evidence of clinically relevant physical dysmorphology indicative of a genetic syndrome as assessed by the PIs or other investigators, including a medical geneticist and psychiatrists trained in identifying dysmporphic features associated with neurodevelopmental conditions. - Current/Prior Therapy: - History of prior cell therapy - Current or prior use of IVIG or other anti-inflammatory medications with the exception of NSAIDs - No systemic steroid therapy that has lasted >2 weeks, and no systemic steroids within 3 months prior to enrollment. Topical and inhaled steroids are permitted.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous umbilical cord blood
Single infusion of autologous umbilical cord blood cells
Placebo
Placebo

Locations

Country Name City State
Israel Chaim Seba Medical Center Ramat Gan

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (3)

Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Lee LC, Pettygrove S, Robinson C, Schulz E, Wells C, Wingate MS, Zahorodny W, Yeargin-Allsopp M; Centers for Disease Control and Prevention (CDC). Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years--Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ. 2016 Apr 1;65(3):1-23. doi: 10.15585/mmwr.ss6503a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2016;65(15):404. — View Citation

Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014 Mar 8;383(9920):896-910. doi: 10.1016/S0140-6736(13)61539-1. Epub 2013 Sep 26. Review. — View Citation

Prata J, Santos SG, Almeida MI, Coelho R, Barbosa MA. Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations. J Neuroinflammation. 2017 Sep 4;14(1):179. doi: 10.1186/s12974-017-0938-y. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of social communication skills Vineland Adaptive Behavior Scales-Second Edition (VINELAND-II) 6 months
Primary Improvement of social communication skills Pediatric Evaluation of Disability Inventory-Computer Adaptive Test-ASD 6 months
Secondary Improvement of social communication skills Theory of Mind Inventory - 2 6 months
Secondary Functional assessment Adaptive Behavior Assessment System - Second edition (ABAS-2) 6 months
See also
  Status Clinical Trial Phase
Completed NCT05497167 - Development and Evaluation of "Period Kits" for Adolescents With Intellectual and Developmental Disabilities N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT06086964 - Effect of Therapeutic Diet With Physiotherapy on Gross Motor and Cognition of Autistic Children N/A
Not yet recruiting NCT05302544 - Impact of Mixed Reality Training on Motor Skills in Children With Autistic Spectrum Disorder N/A
Completed NCT03957044 - the Effect of Vestibular Rehabilitation in Autistic Children N/A
Recruiting NCT06272669 - Cumulative and Booster Effects of Multisession Prefrontal tDCS in Adolescents With ASD N/A
Recruiting NCT05492032 - Cumulative and Booster Effects of Multisession Prefrontal tDCS in Adolescents With ASD N/A
Completed NCT02057809 - "Family-centered" Pediatric Rehabilitation Services in Children With Developmental Disabilities
Completed NCT04007224 - Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder Phase 1
Completed NCT05077020 - Somatic Diseases in Autistic Children
Completed NCT05025553 - Oral Administration of Polyethylene Glycol (PEG) for 6 Months in Chronically Constipated Autistic Children N/A
Completed NCT04261595 - Dates as a Functional Food for Autism N/A
Completed NCT05515913 - Nutritional Status and ASD Severity of Autistic Spectrum Disorder Children in Addis Ababa, Ethiopia; Case Control Study
Completed NCT05875363 - Neurodevelopmental Disorders in Youth With Criminal Behaviors